Filspari drives strong royalty growth while legal risks persist
- Ligand is a biotech royalty aggregator, earning revenue when partners successfully sell drugs.
- Third quarter 2026 royalty revenue jumped 51 percent year over year to $70.3 million.
- Filspari overtook Kyprolis as the largest royalty asset, proving the portfolio can replace older declining cash flows.
- The closed XOMA acquisition added over 120 assets and more than $110 million in tax attributes.
- Key risks include expected XOMA integration litigation and a cross-complaint from Viking Therapeutics.
New assets step up as legacy drugs fade
Ligand offers a leaner way to invest in biotech upside. It does not need to build large sales teams for every new drug. Instead, it owns royalty rights and gets paid when partner therapies reach patients.
The investment thesis strengthened in the third quarter of 2026 as royalty revenue surged 51 percent year over year to $70.3 million. More importantly, newer growth engines like Filspari finally overtook older assets like Kyprolis in total contribution. This validates management's strategy of deploying capital to outgrow incoming generic patent cliffs. The recent XOMA acquisition also adds massive diversification and tax benefits.
However, new scale brings new pressures. Older cash cows are already declining in sales, and generic competition for Evomela is a reality. Legal risks are also rising. Management expects litigation related to the XOMA deal, and Viking Therapeutics filed a formal cross-complaint in July 2026 over a canceled program.
Finn sees a complex transition. Business performance and growth are solid, but valuation scores suggest the market remains cautious. Ligand must now prove it can integrate XOMA cheaply, navigate legal challenges, and deploy its new capital wisely without overpaying.
Collecting payments when partners win
Ligand makes money in three main ways: royalties on partnered drugs, sales of Captisol material, and contract revenue from milestone fees. Royalties are the core growth engine, reaching $70.3 million in the third quarter of 2026.
This model can be highly profitable. Ligand collects from many drug programs while keeping its own cost base small. The XOMA acquisition highlights this efficiency, with management expecting to run those new assets on less than $5 million in operating expenses.
The major tradeoff is control. Ligand does not run the drug trials or sales launches. If a partner struggles with a rollout or a drug faces generic competition, Ligand's cash flow falls even if its own team performed perfectly.
Capital allocation is the critical lever. Ligand relies on buying or funding royalty rights at attractive prices. With a large deployable capital base, the discipline to avoid overpaying for assets in the sub-$100 million deal market will define the company's next phase.
A diversified royalty basket
Filspari
Travere's drug is approved for IgAN and FSGS. It generated an estimated $16.8 million in the third quarter of 2026, becoming Ligand's largest royalty asset.
XOMA royalty portfolio
The closed acquisition added over 120 assets to the mix, heavily diversifying the pipeline and adding exposure to Roche's Vabysmo.
Kyprolis and Evomela
These older royalties face generic pressure. Kyprolis sales continue to decline, and Evomela generics are actively entering the market.
Ohtuvayre
A newer asset driving strong top-line momentum following its launch by Merck for the maintenance treatment of COPD.
Captisol
Captisol is a drug solubility technology. Revenue is uneven because customer orders shift unpredictably between quarters.
Qtorin rapamycin
A pipeline asset with Palvella. The FDA accepted the NDA for priority review, setting a target action date of February 28, 2027.
Heavily weighted to royalties
The mix uses Q1 2026 revenue categories for structural consistency. Royalties remain the undisputed primary revenue driver, exceeding $70 million in Q3 2026.
What could break the growth engine
Generic cliffs in older royalties
High impact · High oddsRoyalty assets have finite lives. Kyprolis sales are falling, and Evomela faces generic competition. New assets must scale fast enough to replace this lost cash.
Viking TR-Beta dispute escalation
High impact · Medium oddsViking filed a cross-complaint in July 2026 alleging breach of contract after Ligand terminated the TR-Beta program. A negative outcome could result in high legal costs or lost economics.
XOMA litigation and integration
Medium impact · High oddsManagement explicitly expects litigation in connection with the closed XOMA acquisition. The company also promised to run the new portfolio cheaply, a target that could be missed if integration falters.
Partner execution risk
High impact · Medium oddsLigand depends on partners to win approvals and sell drugs. Delayed timelines, like Mirum's PSC submission pushing to 2027, defer expected returns.
Capital deployment discipline
High impact · Medium oddsLigand has significant deployable capital. While this provides dry powder, having excess cash can tempt management to overpay for assets in a competitive market.
In one breath
What does Ligand Pharmaceuticals actually do?
Ligand owns rights to payments from drugs that other companies develop and sell. It also licenses technologies like Captisol, which helps make certain drugs easier to formulate.
Why is the XOMA acquisition important for Ligand?
XOMA added over 120 assets to Ligand's portfolio, instantly diversifying revenue. The deal also brought valuable tax attributes while testing management's integration skills.
Is Ligand a normal biotech company?
No. A normal biotech spends heavily to discover and sell its own drugs. Ligand operates more like a royalty owner, meaning partner success dictates its cash flow.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Ligand Pharmaceuticals Incorporated in Finn's Biotechnology industry ranking.

